Policy and Procedures for Developing the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings
Title: Policy and Procedures for Developing the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings
Anticipated Date of Dissemination: April 2018
Subject: Hazardous Drug Exposure in Healthcare Settings
Purpose: To describe the internal practices used by NIOSH to add or remove pharmaceutical substances to/from the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings.
Agency contact for information: hazardousdrugs@cdc.gov
Timing of Review: December 20, 2017 – February 9, 2018
Primary Disciplines or Expertise Needed for Review: pharmacy, nursing, pharmacology, occupational health, toxicology, veterinary medicine
Type of Review: Individual letters
Number of Reviewers: 4 — 10
Reviewers Selected by: CDC/NIOSH
Public Nominations Requested for Review Panel: No
Opportunities for the Public to Comment: Yes, Provide comments on this plan via email to the Agency contact identified above
Peer Reviewers Provided with Public Comments Before Their Review: No
The National Institute for Occupational Safety and Health (NIOSH) of the Centers for Disease Control and Prevention (CDC) announces the availability for public comment on the peer review plan for the NIOSH Policy and Procedures for Developing the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. The NIOSH Director has developed draft policy and procedures, entitled Policy and Procedures for Developing the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, to formalize the methodology NIOSH uses to guide the addition of hazardous drugs to the List.